Etoricoxib has been in use for treatment of Rheumatoid arthritis for several years. In study, the microparticles are prepared of etoricoxib loaded in graphene oxide & transmitted through intra-articular administration in joint cavity. The absorbance maxima of the test drug in ethanol were observed at 284µm which perfectly matched the standard value given in E.P It was observed that the test drug is freely soluble in ethanol, methanol and soluble in phosphate buffer pH 7.4 Modified solvent evaporation technique was selected due to easy recovery of particles and on evaluation of particle size they were found in Micro range. pH of the prepared Microparticle was found to be 7.54 which is in blood buffer range. The % cumulative release of the prepared formulations is given as ET4 98.61% (1:2 drug: carrier ratio) > ET2 97.57% (1:3) > ET5 96.34% (1:3) > ET6 95.27 % (1:4) > ET3 94.8% (1:5) >ET1 93.33% (1:6). A burst release was not observed for any of the formulations, this may be due to better entrapment of drug into carrier matrix. From the observed values it may be concluded that release rate of the drug not solely depends on carrier concentration but also a texture, loading capacity and surface morphology. After comparing different evaluation parameters like percentage yield, particle size, zeta potential. PDI, percentage entrapment efficiency and in-vitro diffusion study ET4 was selected as the best optimized formulation. The particle size of the formulation ET4 was reported as 18.1µm, percentage yield as 57%, zeta potential as -18.2 within 96.5%, PDI as 0.248. % entrapment efficiency as 99.36% and in-vitro diffusion as 98.41% in study period. Hence, it was concluded that formulation ET4 can be used for further study.